Somatic alterations contributing to metastasis of a castration-resistant prostate cancer

Michael L. Nickerson, Kate M. Im, Kevin J. Misner, Wei Tan, Hong Lou, Bert Gold, David W. Wells, Hector C. Bravo, Karin M. Fredrikson, Timothy T. Harkins, Patrice Milos, Berton Zbar, W. Marston Linehan, Meredith Yeager, Thorkell Andresson, Michael Dean, G. Steven Bova

Research output: Contribution to journalArticle

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty-two somatic variants altered proteins in tumors, including cancer-associated genes, TMPRSS2-ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next-generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2-ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease.

Original languageEnglish (US)
Pages (from-to)1231-1241
Number of pages11
JournalHuman Mutation
Volume34
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Castration
Prostatic Neoplasms
Neoplasm Metastasis
Neoplasms
Exome
Chronology
Germ-Line Mutation
Loss of Heterozygosity
Neoplasm Genes
DNA Sequence Analysis
Single Nucleotide Polymorphism
Disease Progression
Kidney
Mutation
Genes
Proteins

Keywords

  • BRCA1
  • Epigenetic modifiers
  • ERG
  • Metastasis
  • PBRM1
  • Somatic mutation
  • TET2
  • TMPRSS2
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Nickerson, M. L., Im, K. M., Misner, K. J., Tan, W., Lou, H., Gold, B., ... Bova, G. S. (2013). Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Human Mutation, 34(9), 1231-1241. https://doi.org/10.1002/humu.22346

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. / Nickerson, Michael L.; Im, Kate M.; Misner, Kevin J.; Tan, Wei; Lou, Hong; Gold, Bert; Wells, David W.; Bravo, Hector C.; Fredrikson, Karin M.; Harkins, Timothy T.; Milos, Patrice; Zbar, Berton; Linehan, W. Marston; Yeager, Meredith; Andresson, Thorkell; Dean, Michael; Bova, G. Steven.

In: Human Mutation, Vol. 34, No. 9, 09.2013, p. 1231-1241.

Research output: Contribution to journalArticle

Nickerson, ML, Im, KM, Misner, KJ, Tan, W, Lou, H, Gold, B, Wells, DW, Bravo, HC, Fredrikson, KM, Harkins, TT, Milos, P, Zbar, B, Linehan, WM, Yeager, M, Andresson, T, Dean, M & Bova, GS 2013, 'Somatic alterations contributing to metastasis of a castration-resistant prostate cancer', Human Mutation, vol. 34, no. 9, pp. 1231-1241. https://doi.org/10.1002/humu.22346
Nickerson, Michael L. ; Im, Kate M. ; Misner, Kevin J. ; Tan, Wei ; Lou, Hong ; Gold, Bert ; Wells, David W. ; Bravo, Hector C. ; Fredrikson, Karin M. ; Harkins, Timothy T. ; Milos, Patrice ; Zbar, Berton ; Linehan, W. Marston ; Yeager, Meredith ; Andresson, Thorkell ; Dean, Michael ; Bova, G. Steven. / Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. In: Human Mutation. 2013 ; Vol. 34, No. 9. pp. 1231-1241.
@article{776172e4d4ae4867a34a5abbdac07b09,
title = "Somatic alterations contributing to metastasis of a castration-resistant prostate cancer",
abstract = "Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty-two somatic variants altered proteins in tumors, including cancer-associated genes, TMPRSS2-ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next-generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2-ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease.",
keywords = "BRCA1, Epigenetic modifiers, ERG, Metastasis, PBRM1, Somatic mutation, TET2, TMPRSS2, Tumor heterogeneity",
author = "Nickerson, {Michael L.} and Im, {Kate M.} and Misner, {Kevin J.} and Wei Tan and Hong Lou and Bert Gold and Wells, {David W.} and Bravo, {Hector C.} and Fredrikson, {Karin M.} and Harkins, {Timothy T.} and Patrice Milos and Berton Zbar and Linehan, {W. Marston} and Meredith Yeager and Thorkell Andresson and Michael Dean and Bova, {G. Steven}",
year = "2013",
month = "9",
doi = "10.1002/humu.22346",
language = "English (US)",
volume = "34",
pages = "1231--1241",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Somatic alterations contributing to metastasis of a castration-resistant prostate cancer

AU - Nickerson, Michael L.

AU - Im, Kate M.

AU - Misner, Kevin J.

AU - Tan, Wei

AU - Lou, Hong

AU - Gold, Bert

AU - Wells, David W.

AU - Bravo, Hector C.

AU - Fredrikson, Karin M.

AU - Harkins, Timothy T.

AU - Milos, Patrice

AU - Zbar, Berton

AU - Linehan, W. Marston

AU - Yeager, Meredith

AU - Andresson, Thorkell

AU - Dean, Michael

AU - Bova, G. Steven

PY - 2013/9

Y1 - 2013/9

N2 - Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty-two somatic variants altered proteins in tumors, including cancer-associated genes, TMPRSS2-ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next-generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2-ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease.

AB - Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty-two somatic variants altered proteins in tumors, including cancer-associated genes, TMPRSS2-ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next-generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2-ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease.

KW - BRCA1

KW - Epigenetic modifiers

KW - ERG

KW - Metastasis

KW - PBRM1

KW - Somatic mutation

KW - TET2

KW - TMPRSS2

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84881617298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881617298&partnerID=8YFLogxK

U2 - 10.1002/humu.22346

DO - 10.1002/humu.22346

M3 - Article

C2 - 23636849

AN - SCOPUS:84881617298

VL - 34

SP - 1231

EP - 1241

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 9

ER -